A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin

Autor: Gc, Ibeanu, Blaisdell J, Rj, Ferguson, Bi, Ghanayem, Brosen K, Simone BENHAMOU, Bouchardy C, Gr, Wilkinson, Dayer P, Ja, Goldstein

Publikováno v: Europe PubMed Central

Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::138995eb67d62e43fcbf35c936163456
https://pubmed.ncbi.nlm.nih.gov/10411572

Influence of genetic polymorphism on the metabolism and disposition of encainide in man

Autor: Wang T, Dm, Roden, Ht, Wolfenden, Raymond L. Woosley, Aj, Wood, Gr, Wilkinson

Publikováno v: Europe PubMed Central

The metabolism of the new, highly effective antiarrhythmic agent, encainide, appears to be polymorphically distributed in a similar fashion to the genetically determined oxidative biotransformation of debrisoquine. Accordingly, the disposition of enc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f24d74b20f4f48fbfdb863db99004356
https://pubmed.ncbi.nlm.nih.gov/6423808

Comparing coordination uranyl(vi) complexes with 2-(1H-imidazo[4,5-b]phenazin-2-yl)phenol and derivatives.

Autor: Hiti EA; Department of Chemistry and Biochemistry, Auburn University, Auburn, AL 36849, USA., Wilkinson GR, Ariyarathna IR, Tutson CD, Hardy EE, Maynard BA, Miliordos E, Gorden AEV

Publikováno v: Dalton transactions (Cambridge, England : 2003) [Dalton Trans] 2021 Aug 28; Vol. 50 (32), pp. 11113-11122. Date of Electronic Publication: 2021 Jul 29.

Sedative Plasma Concentrations and Delirium Risk in Critical Illness.

Autor: Stollings JL; 1 Vanderbilt University Medical Center, Nashville, TN, USA., Thompson JL; 2 Vanderbilt University School of Medicine, Nashville, TN, USA., Ferrell BA; 1 Vanderbilt University Medical Center, Nashville, TN, USA.; 3 University of Tennessee School of Medicine, Nashville, TN, USA., Scheinin M; 4 University of Turku, Turku, Finland.; 5 Turku University Hospital, Turku, Finland., Wilkinson GR; 1 Vanderbilt University Medical Center, Nashville, TN, USA.; 2 Vanderbilt University School of Medicine, Nashville, TN, USA., Hughes CG; 1 Vanderbilt University Medical Center, Nashville, TN, USA.; 2 Vanderbilt University School of Medicine, Nashville, TN, USA., Shintani AK; 2 Vanderbilt University School of Medicine, Nashville, TN, USA.; 6 Osaka University, Suita, Japan., Ely EW; 1 Vanderbilt University Medical Center, Nashville, TN, USA.; 2 Vanderbilt University School of Medicine, Nashville, TN, USA.; 7 Veterans Affairs, Tennessee Valley Health Care System, Nashville, TN, USA., Girard TD; 8 University of Pittsburgh School of Medicine, PA, USA., Pandharipande PP; 1 Vanderbilt University Medical Center, Nashville, TN, USA.; 2 Vanderbilt University School of Medicine, Nashville, TN, USA.; 7 Veterans Affairs, Tennessee Valley Health Care System, Nashville, TN, USA., Patel MB; 1 Vanderbilt University Medical Center, Nashville, TN, USA.; 2 Vanderbilt University School of Medicine, Nashville, TN, USA.; 7 Veterans Affairs, Tennessee Valley Health Care System, Nashville, TN, USA.

Publikováno v: The Annals of pharmacotherapy [Ann Pharmacother] 2018 Jun; Vol. 52 (6), pp. 513-521. Date of Electronic Publication: 2018 Jan 24.

Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein.

Autor: Kurnik D; Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA., Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, Muszkat M

Publikováno v: Anesthesiology [Anesthesiology] 2008 Dec; Vol. 109 (6), pp. 1092-9.